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Preoperative positron emission tomography/computed tomography (PET/CT) was performed in 26 consecutive
patients considered fit for aneurysm repair. Besides information on aneurysm wall pathology, PET/CT identified 6
patients with concomitant malignancy. As a result of this coincidental finding, the operation was postponed in 2 patients
and cancelled in 1. Although previous studies have shown that PET/CTmight affect patient selection based on aneurysm
wall inflammation, our preliminary results show a big impact on patient management as a result of the sensitivity of
PET/CT for detecting malignancy. Future larger studies are warranted to investigate the effect and cost effectiveness of
routine PET/CT in abdominal aortic aneurysm (AAA) patients. ( J Vasc Surg 2009;49:1313-5.)CASE REPORT
Because of considerable risks associated with prophylactic
aneurysm repair, patient selection for surgery should include an
accurate assessment of aneurysm rupture risk and the identification
of co-morbid medical conditions that might limit life expectancy.1
Recently integrated positron emission and computed tomog-
raphy (PET/CT) has been proposed as a promising technique that
could provide information on aneurysmwall pathology (inflamma-
tion) and improve rupture risk prediction.2,3 Clinically, PET/CT
is used for diagnosis and follow-up of several malignancies and
routine preoperative PET/CT could therefore not only provide
information on aneurysm disease but also on possible co-morbid
conditions limiting life expectancy in aneurysm patients. This case
series describes the preliminary results of a larger prospective study
conducted to evaluate aneurysmwall inflammation using PET/CT
and the possible impact of routine preoperative PET/CT on
patient selection for prophylactic aneurysm repair.
MATERIALS AND METHODS
After routine preoperative assessment of pulmonary
and cardiac functions, abdominal computed tomographic
angiography (CTA) and chest x-ray, 26 consecutive aneu-
rysm patients were considered fit for prophylactic surgical
repair. PET/CT was performed at hospital admission, the
day before surgery. The institutes’ ethical review board
approved the study protocol and signed informed consent
was obtained from all patients. None of the patients pre-
sented with aneurysm rupture or symptoms related to
pending aneurysm rupture (eg, lower back pain). However,
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related to rapid aneurysm expansion or pending rupture.
PET/CT imaging after injection of fluorodeoxyglu-
cose (FDG) was performed using an integrated PET and
dual slice CT scanner (Biograph Duo, Siemens Medical
Solutions, Knoxville, Tenn). Low dose CT and PET data
acquisition started 1 hour after intravenous administration
of 200-220 MBq FDG (Covidien, Petten, The Nether-
lands). PET imaging included emission images of the area
between proximal femora and the base of the skull. CT
scanning parameters included 40 mA and a tube voltage of
130 kV. After PET and CT data fusion, the images were
analyzed by physicians experienced in combined PET and
CT interpretation.
RESULTS
Patient demographics are listed in Table I. In 6 of 26
patients (23%, 95% confidence interval 11-42%), PET/CT
identified malignancy not detected by standard preopera-
tive abdominal CTA and chest x-ray.
Five patients were diagnosed with pulmonary carci-
noma, and 1 patient was diagnosed with endometrial car-
cinoma (Fig). The operation was cancelled in 1 patient
because of extensive lymph node metastasis (Table II). For
the purpose of cancer staging, endovascular aneurysm re-
pair (EVAR) was postponed in 2 patients (48 and 24 days
after PET/CT, respectively). In the remaining 3 patients,
the operationwas performed as scheduled, after informing the
patient and consulting a pulmonary physician. The decision to
proceed with the operation was made because of limited
disease (no lymph node involvement) or a history of abdom-
inal aortic aneurysm (AAA)-related symptoms (lower back
pain). Two patients died of non-small cell lung cancer within
3 months after PET/CT and 1 patient died of endometrial
carcinoma 9 months after PET/CT.
DISCUSSION
After routine preoperative CTA and chest x-ray,
PET/CT identified previously undiagnosed malignancy in
1313
on the right (red circle). PET, Positron emission tomography
CT) identified previously undiagnosed malignancy in 6 patients.
Continuous data is reported using median and interquartile range.
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repair. Although literature on the effect of concurrent
malignancy on postoperative survival in aneurysm patients
is limited, the present study shows that routine preoperative
PET/CT could have a big impact on patient selection for
aneurysm repair.
The high prevalence of cardiovascular and pulmonary
disease, together with the important impact on both oper-
ative and long-term survival following aneurysm repair calls
for routine preoperative evaluation of cardiac and pulmo-
nary functions.4 In contrast to cardiac and pulmonary
disease, little data exist on the impact of concomitant
malignancy on survival after aneurysm repair.5 The re-
ported incidence of cancer among aneurysm patients is,
however, high and estimated between 4 and 13%.6 More-
over, Valentine et al6 showed a higher incidence of cancer
among AAA patients when compared to an age matched
population, indicative for a true association between aneu-
rysm disease and malignancy.
Although routine preoperative CTA and chest x-ray
could have revealed previously undiagnosedmalignancy, all
patients included in this study were considered to be fit for
a patient scheduled for aneurysm repair. The top row
le on the CT (middle row) and fused image (bottom row)Fig. Incidental finding of endometrial carcinoma (arrow) in
shows the PET image. The abdominal aortic aneurysm is visibTable I. Patient characteristics
Patient characteristics Patients (n  26)
Age (years) 71 (64-75)
AAA size 58 (55-65)
Male 24 (92%
Tumora 6 (23%)
CAD 7 (27%)
COPD 8 (31%)
CVD 2 (8%)
Diabetes 1 (4%)
Current smoking 9 (35%)
Aspirin use 26 (100%)
Statin use 26 (100%)
Antihypertensive treatment 26 (100%)
CAD, History of coronary artery disease; COPD, chronic obstructive pul-
monary disease; CVD, history of cerebral vascular disease; AAA, abdominal
aortic aneurysm.
aAfter routine preoperative computed tomographic angiography (CTA) and
chest x-ray, positron emission tomography/computed tomography (PET/; CT, computed tomography.
aneur
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high number of patients with concurrent cancer detected
by PET/CT, therefore, reflects the superiority of com-
bined PET/CT over CT alone for the detection of malig-
nancy.7-9 Because of the advantages of PET/CT imaging for
detecting and staging cancer, PET/CT scanners are available
inmost university and tertiary care hospitals.Moreover, in the
past 7 years over 2500 PET/CT scanners have been installed
worldwidewhich underscores the acceptance of PET/CT as a
new standard in oncologic imaging.10
Possible drawbacks for the routine preoperative use of
PET/CT in aneurysm patients is the associated increased
exposure to radiation. In the current study, using low dose
CT and FDG-PET, radiation dose is an estimated 2-4 mSv
per patient. Compared to conventional CT (average 7-20
mSv) and according to the 62nd publication of the Inter-
national Commission on Radiological Protection (IRCP)
this is considered a minor to intermediate radiation expo-
sure.11 PET imaging could be performed in combination
with the standard diagnostic preoperative CTA. As this will
result in additional costs (approximately 1500 USD), fu-
ture studies should also consider the cost effectiveness of
additional PET imaging in the perspective of improved
patient selection for aneurysm repair.
In conclusion, FDG-PET/CT has the potential to detect
previously undiagnosed malignancy in a population of AAA
patients considered fit for prophylactic aneurysm repair. Be-
cause of the high incidence of cancer among aneurysm pa-
tients and the impact of concomitant malignancy on life
expectancy and timing of surgical repair, further studies are
warranted to investigate the necessity and cost effectiveness of
Table II. Characteristics and outcome of patients diagnos
Patient Gender Age
AAA size
(mm)
History of
AAA related
symptoms
PET/CT fin
up
1 M 68 41 Yes Left lung Med
nodes. Ven
2 F 56 55 No Right lung. N
the AAA wa
3 F 75 59 No Endometrium
the AAA wa
4 M 71 50 No Right lung M
lymph node
in the AAA
5 M 72 57 No Left lung. No
AAA wall.
6 M 71 61 Yes Right lung, M
lymph node
in the AAA
1FDG, Fluorodeoxyglucose is radioactive labeled glucose uptake depicting
FDG uptake is considered significant when the region of interest (AAA or t
2EVAR, Endovascular aneurysm repair; 3OR, Open repair or conventional
tomography/computed tomography.routine preoperative cancer screening in AAA patients.REFERENCES
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